Form 8-K
Table of Contents

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): April 11, 2003

 


 

RESPIRONICS, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware

 

000-16723

 

25-1304989

(State or Other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification Number)

1010 Murry Ridge Lane

Murrysville, Pennsylvania

     

15668-8525

(Address of Principal Executive Offices)

     

(Zip Code)

   

724-387-5200

   
   

(Registrant’s telephone number,

including area code)

   

 



Table of Contents

TABLE OF CONTENTS

 

Item 9. REGULATION FD DISCLOSURE.

 

SIGNATURES

INDEX TO EXHIBITS

EX-99 PRESS RELEASE

 

2

 



Table of Contents

 

Item 9.    REGULATION FD DISCLOSURE.

 

The following information is furnished pursuant to Item 12, “Disclosure of Results of Operations and Financial Condition.”

 

On April 11, 2003, Respironics Inc. issued a press release announcing its plans to consolidate acquired product lines and functions. In that press release, Respironics, Inc. also reported that it expects to report earnings for the third quarter of fiscal year 2003 in line with its previous guidance. A copy of the press release is attached hereto as Exhibit 99.

 

Exhibits

 

99        Press release, dated April 11, 2003, issued by Respironics, Inc.

 

3

 


 


Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

RESPIRONICS, INC.

   

/s/    Daniel J. Bevevino                            

   

Daniel J. Bevevino

   

Vice President, and Chief Financial and

   

Principal Accounting Officer

Dated: April 11, 2003

   

 

4

 


 


Table of Contents

INDEX TO EXHIBITS

 

Exhibit No.


  

Description


99

  

Press release, dated April 11, 2003, issued by Respironics, Inc.

 

 

5